ArticleCells2020
Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer.
Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Prognostic superiority of volumetric PET parameters (MTV and TLG) over SUV in advanced non-small-cell lung cancer: a systematic review and meta-analysis of univariate and multivariate evidence.Frontiers in immunology · 2026Pooled it
- Pooled it
- Tumor-Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy-Immunotherapy Combination Trials.International journal of cancer · 2026Review
- The Relationship Between Immunogenic Cell Death and Cellular Senescence in Cancer Immunotherapy.Life (Basel, Switzerland) · 2026Review
- Improved early response assessment of chemoimmunotherapy efficacy byEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Review
- Article
- Integrated transcriptomic analysis and machine learning identify immunogenic cell death genes as prognostic markers and therapeutic targets in non-small cell lung cancer.Translational cancer research · 2026Article
- Immunogenic cell death as a cornerstone for combination therapies with immune checkpoint blockade.Molecular cancer · 2026Review
- E3 ligase LMO7 enhances temozolomide sensitivity by promoting MGMT degradation in lung cancer.The Journal of biological chemistry · 2026Article
- Integration of immunogenic cell death in the treatment landscape of non-small cell lung cancer: harnessing the power of the immune system.Cell death discovery · 2026Review
- Drug Delivery Systems Repurposing Taxanes as Antitumor Immune Modulators.Biomaterials research · 2026Review
- Advances in neoadjuvant immunotherapy for non-small cell lung cancer.Frontiers in immunology · 2026Review
- Therapeutic targeting of cell death-immune crosstalk in cancer to rewire the tumor immune microenvironment.Molecular cancer · 2025Review
- Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer.Cancer immunology, immunotherapy : CII · 2025Article
- Cyclometalated iridium(III) complex based on isoquinoline alkaloid synergistically elicits the ICD response and IDO inhibitionActa pharmaceutica Sinica. B · 2025Article
- Cu(II) complex that synergistically potentiates cytotoxicity and an antitumor immune response by targeting cellular redox homeostasis.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Implications of different cell death patterns for prognosis and immunity in lung adenocarcinoma.NPJ precision oncology · 2023Article
- Marine natural product lepadin A as a novel inducer of immunogenic cell death via CD91-dependent pathway.Natural products and bioprospecting · 2023Article
- Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds.Cancer cell international · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The concept of immunogenic cell death (ICD) has emerged as a cornerstone of therapy-induced anti-tumor immunity. To this end, the following chemotherapies were evaluated for their ability to induce ICD in non-small cell lung cancer (NSCLC) cell lines: docetaxel, carboplatin, cisplatin, oxaliplatin and mafosfamide. The ICD hallmarks ATP, ecto-calreticulin, HMGB1, phagocytosis and maturation status of dendritic cells (DCs) were assessed in vitro. Furthermore, an in vivo vaccination assay on C57BL/6J mice was performed to validate our in vitro results. Docetaxel and the combination of docetaxel with carboplatin or cisplatin demonstrated the highest levels of ATP, ecto-calreticulin and HMGB1 in three out of four NSCLC cell lines. In addition, these regimens resulted in phagocytosis of treated NSCLC cells and maturation of DCs. Along similar lines, all mice vaccinated with NSCLC cells treated with docetaxel and cisplatin remained tumor-free after challenge. However, this was not the case for docetaxel, despite its induction of the ICD-related molecules in vitro, as it failed to reject tumor growth at the challenge site in 60% of the mice. Moreover, our in vitro and in vivo data show the inability of oxaliplatin to induce ICD in NSCLC cells. Overall with this study we demonstrate that clinically relevant chemotherapeutic regimens in NSCLC patients have the ability to induce ICD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.